Abstract Number: 0498 • ACR Convergence 2020
Exploring the Role of Lipocalin-2 in Neuropsychiatric SLE Pathogenesis
Background/Purpose: While the etiology of neuropsychiatric lupus (NPSLE) is not fully understood, blood brain barrier (BBB) disruption and localized neuroinflammation are potential mechanisms that contribute…Abstract Number: 0618 • ACR Convergence 2020
The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus
Background/Purpose: The United States has a deficit of rheumatology specialists. This leads to an increased burden accessing care for patients with autoimmune and connective tissue…Abstract Number: 0852 • ACR Convergence 2020
How Much Prednisone Is Enough for Remission Induction in Lupus Nephritis? A Propensity Score Matched Analysis
Background/Purpose: The existing guidelines for remission induction in lupus nephritis (LN) from both the ACR and the EULAR recommend initial prednisone doses of 0.5-1mg/kg/day. However,…Abstract Number: 0870 • ACR Convergence 2020
Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vascular Health in Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of premature atherosclerosis and thrombosis. Hydroxychloroquine (HCQ) is widely used in the treatment of…Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…Abstract Number: 1131 • ACR Convergence 2020
Patient Perspective of Helpfulness of Lupus Medications: A Qualitative Study of Medication Use Within the Type 1 and 2 SLE Model
Background/Purpose: Medication management in systemic lupus erythematosus (SLE) is particularly complex given the clinical heterogeneity of symptoms and a wide range of medications used. We…Abstract Number: 1267 • ACR Convergence 2020
Perceived Stress During the COVID-19 Pandemic Independently Associates with Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
Background/Purpose: Causes and risk factors for variations in SLE disease activity and symptom severity are incompletely understood. Prior studies suggest a link between stressful life…Abstract Number: 1283 • ACR Convergence 2020
Factors Affecting Mortality of Systemic Lupus Erythematosus Patients in Spain in the 21st Century: Data from the RELESSER Registry
Background/Purpose: The mortality in Systemic Lupus Erythematosus (SLE) varies largely across different countries most probably due to social, healthcare and ethnic differences.To analyze the causes…Abstract Number: 1299 • ACR Convergence 2020
Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Background/Purpose: Almost 40% of patients with SLE have comorbid mental health conditions.1 Though depression is most commonly reported (24% to 30%), many SLE patients also…Abstract Number: 1509 • ACR Convergence 2020
Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
Background/Purpose: Childhood-onset SLE is generally more aggressive than adult-onset SLE. Leukocyte telomere length (LTL) has been posited to reflect immune system aging. Short LTL in…Abstract Number: 1666 • ACR Convergence 2020
Elucidating Research Priorities in Childhood-Onset Systemic Lupus Erythematosus: A Qualitative Study
Background/Purpose: An estimated 15 to 20% of patients with systemic lupus erythematosus (SLE) have childhood-onset SLE (cSLE). Given the early onset of cSLE, patients often…Abstract Number: 1766 • ACR Convergence 2020
Trends of Pregnancy Outcomes in a Large Electronic Health Record Cohort of Systemic Lupus Erythematosus Patients
Background/Purpose: Studying pregnancy in systemic lupus erythematosus (SLE) is difficult given its relative rarity. Electronic health record (EHR) contain longitudinal data to serve as a…Abstract Number: 1797 • ACR Convergence 2020
A Multianalyte Assay Panel (MAP) with Algorithm Containing Cell-Bound Complement Activation Products (CB-CAPs) Is Superior to Anti-dsDNA and Low Serum Complement Levels in Predicting Transition of Probable Lupus to ACR Classified Lupus Within 2 Years
Background/Purpose: We reported previously (Ramsey-Goldman et al., Arthritis Rheumatol 2020) that score > 0.8 of a multianalyte assay panel (MAP) with algorithm predicts fulfillment of…Abstract Number: 1815 • ACR Convergence 2020
Dynamic Changes in Microbiota Representation of a Gut Pathobiont and Clinical Disease Activity in Patients with Lupus Nephritis
Background/Purpose: From a cross-sectional cohort, we have recently identified a candidate human gut pathobiont, Ruminococcus gnavus (RG) of the Lachnospiraceae family and Blautia genus that…Abstract Number: 1831 • ACR Convergence 2020
Biomarkers Linked to Anti-IFN-I and Ustekinumab Suggest Distinct Mechanism of Action in Systemic Lupus Erythematosus
Background/Purpose: Clinical and biological heterogeneity pose a significant hurdle in SLE, making biomarkers that define patient subsets crucial for developing tailored therapies. Interventional SLE trials…
- « Previous Page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- …
- 150
- Next Page »